Beximco Pharma - eine Perle aus Bangladesch? (Seite 37)
eröffnet am 16.05.07 14:31:40 von
neuester Beitrag 12.02.24 17:39:26 von
neuester Beitrag 12.02.24 17:39:26 von
Beiträge: 559
ID: 1.127.474
ID: 1.127.474
Aufrufe heute: 0
Gesamt: 69.241
Gesamt: 69.241
Aktive User: 0
ISIN: US0885792061 · WKN: A0ETTX · Symbol: BXP
0,3650
GBP
0,00 %
0,0000 GBP
Letzter Kurs 26.04.24 London
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6500 | +25,75 | |
| 6,0000 | +25,00 | |
| 56,69 | +20,00 | |
| 0,6400 | +18,52 | |
| 491,30 | +17,07 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6282 | -11,68 | |
| 8,5000 | -15,00 | |
| 0,7300 | -18,59 | |
| 92,06 | -19,84 | |
| 2,7280 | -29,14 |
Beitrag zu dieser Diskussion schreiben
Feedback
BEXIMCO PHARMACEUTICALS LTD.
News Release
July 31, 2009
Beximco Pharma is first Bangladeshi company to receive GMP Certificate
from National Health Surveillance Agency (Anvisa) of Brazil
Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”), the leading Bangladeshi
pharmaceutical manufacturer and largest pharmaceutical exporter from Bangladesh, is pleased
to announce that it has received GMP Certificate for its facility from National Health Surveillance
Agency (Anvisa) of Brazil. BPL is the first Bangladeshi company to receive this regulatory
approval from Anvisa through a stringent facility audit process.
With an overall pharmaceutical market of approx US 12 billion dollars, Brazil is the second
largest pharmaceutical market in Latin America and the 10th largest in the world. Brazil is also
one of the most stringently regulated and protected pharmaceutical markets in the world.
The National Health Surveillance Agency (Anvisa) of Brazil is an independently administered
autonomous regulatory agency linked to the Ministry of health of Brazil. It is responsible for
conducting assessment and monitoring activities to ensure that medicines & medical devices
available in Brazil are of high standard.
The company is expecting to commence export to Brazil in H2 2009. After Chile, Brazil is the
second Latin American country where the company is going to export pharmaceutical products.
Managing Director of Beximco Pharma Mr. Nazmul Hassan said:
“As a part of our global expansion plan, we have always considered Latin America as a market
with great potential for Beximco Pharma. We have always been the leader and the flagship of
the Bangladesh pharmaceutical industry by setting new trends and exploring new horizons of
export opportunities. In achieving facility approval from a globally recognized regulatory
authority like National Health Surveillance Agency Anvisa of Brazil, BPL has crossed a very
important milestone in its journey to become a global pharmaceutical company. This approval
puts Beximco Pharma in an elite group of manufacturers world-wide who have passed the
rigorous quality standards of the Brazilian government, enabling the Company to manufacture
and export medicines to Brazil. This approval will enable us to have substantial growth in our
international business. ”
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic
pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids.
The Company also manufactures and markets its own branded generics for almost all diseases.
The Company also undertakes contract manufacturing for multinational pharmaceutical
companies. The Company operates from a 20 acre site in Dhaka and currently employs over
2,400 staff.
The Company’s products are sold to retail outlets, medical institutions and other pharmaceutical
manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam,
Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island
and Central American countries and South East Asia, including Singapore and Hong Kong.
News Release
July 31, 2009
Beximco Pharma is first Bangladeshi company to receive GMP Certificate
from National Health Surveillance Agency (Anvisa) of Brazil
Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”), the leading Bangladeshi
pharmaceutical manufacturer and largest pharmaceutical exporter from Bangladesh, is pleased
to announce that it has received GMP Certificate for its facility from National Health Surveillance
Agency (Anvisa) of Brazil. BPL is the first Bangladeshi company to receive this regulatory
approval from Anvisa through a stringent facility audit process.
With an overall pharmaceutical market of approx US 12 billion dollars, Brazil is the second
largest pharmaceutical market in Latin America and the 10th largest in the world. Brazil is also
one of the most stringently regulated and protected pharmaceutical markets in the world.
The National Health Surveillance Agency (Anvisa) of Brazil is an independently administered
autonomous regulatory agency linked to the Ministry of health of Brazil. It is responsible for
conducting assessment and monitoring activities to ensure that medicines & medical devices
available in Brazil are of high standard.
The company is expecting to commence export to Brazil in H2 2009. After Chile, Brazil is the
second Latin American country where the company is going to export pharmaceutical products.
Managing Director of Beximco Pharma Mr. Nazmul Hassan said:
“As a part of our global expansion plan, we have always considered Latin America as a market
with great potential for Beximco Pharma. We have always been the leader and the flagship of
the Bangladesh pharmaceutical industry by setting new trends and exploring new horizons of
export opportunities. In achieving facility approval from a globally recognized regulatory
authority like National Health Surveillance Agency Anvisa of Brazil, BPL has crossed a very
important milestone in its journey to become a global pharmaceutical company. This approval
puts Beximco Pharma in an elite group of manufacturers world-wide who have passed the
rigorous quality standards of the Brazilian government, enabling the Company to manufacture
and export medicines to Brazil. This approval will enable us to have substantial growth in our
international business. ”
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic
pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids.
The Company also manufactures and markets its own branded generics for almost all diseases.
The Company also undertakes contract manufacturing for multinational pharmaceutical
companies. The Company operates from a 20 acre site in Dhaka and currently employs over
2,400 staff.
The Company’s products are sold to retail outlets, medical institutions and other pharmaceutical
manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam,
Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island
and Central American countries and South East Asia, including Singapore and Hong Kong.
Die Gebühren für die Stockdividende wurden auch schon berechnet: 0,00243 Euro je GDR!
Aktueller Kurs von Beximco 166,30 Taka = 1,70 Euro 
Am Freitag in London 50.139 Stück Umsatz, letzter Kurs 0,58 Euro, also immer noch ca. 66 % Abgeld.
Am Freitag in London 50.139 Stück Umsatz, letzter Kurs 0,58 Euro, also immer noch ca. 66 % Abgeld.
Die 6-Monats-Zahlen von Beximco können sich sehen lassen:
Umsatz + 40 %
Gewinn nach Steuern + 105 %
EPS + 56 %
und es wurde ausdrücklich erwähnt, dass ein GDR eine Aktie enthält!
BEXIMCO PHARMACEUTICALS LTD.
30th July, 2009
Half Year Results - 2009
Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) today announces its results for the half year to 30th June 2009.
Highlights
Products and Markets
Strong sales performance during the first half of 2009 - 39.5% growth in domestic market and 47.8% growth in international market, compared to the same period of 2008.
Supplied Oseflu (Oseltamivir 75mg) capsules to a number of Latin & Central American Countries and to local and international Government Agencies & NGOs to help control the Swine Flu (Influenza A, H1N1 virus) outbreak.
Entered into a Long Term Arrangement (LTA) with Asthma Drug Facility (ADF) France, received initial orders and product supply expected to commence shortly.
Marketing authorization received for 32 new products in eight international markets, including one product in Australia.
The Company has developed and registered locally over 50 molecules for launch over the next twelve months, including a number of CFC free HFA based metered dose inhalers (pMDIs). These new products have strengthened the Company's generic product pipeline.
The new projects on ophthalmic products, nebulizer solution and small volume parenterals are now complete. Two nebulizer products have been launched and a number of eye care and injectable products are expected to be launched during the third quarter of 2009. These are all new product lines for the Company.
Corporate
The Company initiated an expansion project last year due to significant demand for BPL's CFC free HFA based metered dose inhalers globally. This has involved construction and installation of a large pMDI production plant and it is estimated that this new plant will be operational by mid 2010.
As part of reorganization, the board appointed Mr. Nazmul Hassan MP, CEO as the Managing Director of the Company. Mr. Rabbur Reza, Director Marketing, was appointed as Chief Operating Officer.
The Company received a Good Manufacturing Practice (GMP) Certificate for its facility from the National Health Surveillance Agency (ANVISA) of Brazil. BPL is the first Bangladeshi company to receive this regulatory approval from ANVISA through a stringent facility audit process. With an overall pharmaceutical market of approx. US 12 billion dollars, Brazil is the second largest pharmaceutical market in Latin America and the 10th largest in the world. Brazil is also one of the most stringently regulated and protected pharmaceutical markets in the world. The Company expects to commence exports to Brazil in H2 2009. After Chile, Brazil is the second Latin American country where the Company is going to export its products.
The Company has now applied for admission of the GDRs issued against stock dividend to be admitted to trading on the London Stock Exchange's AIM market and admission is expected to occur on 4th August 2009. Following admission, the total number of GDRs in issue will be 40,911,186, each representing one ordinary share of Taka 10 and all having voting rights.
Financial
Net Sales increased by 39.5% to Tk. 2,314.71 million (2008: Tk. 1,659.34 million)
Profit before tax increased by 89.7% to Tk. 381.51 million (2008: Tk. 201.10 million)
EPS increased by 56% to Tk. 2.06 (2008: Tk. 1.32)
Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, commented:
"Over the last two years BPL faced serious challenges to sustain the Company's position at home and abroad. Despite these challenges, management have built a strong platform for the Company to grow significantly over the next few years. We have recently received GMP Certificates/Clearance from TGA Australia, Gulf Cooperation Council (GCC) and ANVISA, Brazil for our new oral solid dosage facility and inhaler facility. These approvals are major breakthroughs for the Company and bring us a step closer towards becoming a global pharmaceutical company over the next few years. "
The half yearly accounts can be viewed at the Company's website: www.beximcopharma.com
For further enquiries please contact:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 861 9151, ext.2080
Libertas Capital Corporate Finance
Jakob Kinde / Anthony Rowland
Tel: +44 (0)20 7569 9650
Financial Dynamics
Jonathan Birt / Susan Quigley
Tel: +44 (0)20 7269 7169
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.
The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.
Umsatz + 40 %
Gewinn nach Steuern + 105 %
EPS + 56 %
und es wurde ausdrücklich erwähnt, dass ein GDR eine Aktie enthält!
BEXIMCO PHARMACEUTICALS LTD.
30th July, 2009
Half Year Results - 2009
Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) today announces its results for the half year to 30th June 2009.
Highlights
Products and Markets
Strong sales performance during the first half of 2009 - 39.5% growth in domestic market and 47.8% growth in international market, compared to the same period of 2008.
Supplied Oseflu (Oseltamivir 75mg) capsules to a number of Latin & Central American Countries and to local and international Government Agencies & NGOs to help control the Swine Flu (Influenza A, H1N1 virus) outbreak.
Entered into a Long Term Arrangement (LTA) with Asthma Drug Facility (ADF) France, received initial orders and product supply expected to commence shortly.
Marketing authorization received for 32 new products in eight international markets, including one product in Australia.
The Company has developed and registered locally over 50 molecules for launch over the next twelve months, including a number of CFC free HFA based metered dose inhalers (pMDIs). These new products have strengthened the Company's generic product pipeline.
The new projects on ophthalmic products, nebulizer solution and small volume parenterals are now complete. Two nebulizer products have been launched and a number of eye care and injectable products are expected to be launched during the third quarter of 2009. These are all new product lines for the Company.
Corporate
The Company initiated an expansion project last year due to significant demand for BPL's CFC free HFA based metered dose inhalers globally. This has involved construction and installation of a large pMDI production plant and it is estimated that this new plant will be operational by mid 2010.
As part of reorganization, the board appointed Mr. Nazmul Hassan MP, CEO as the Managing Director of the Company. Mr. Rabbur Reza, Director Marketing, was appointed as Chief Operating Officer.
The Company received a Good Manufacturing Practice (GMP) Certificate for its facility from the National Health Surveillance Agency (ANVISA) of Brazil. BPL is the first Bangladeshi company to receive this regulatory approval from ANVISA through a stringent facility audit process. With an overall pharmaceutical market of approx. US 12 billion dollars, Brazil is the second largest pharmaceutical market in Latin America and the 10th largest in the world. Brazil is also one of the most stringently regulated and protected pharmaceutical markets in the world. The Company expects to commence exports to Brazil in H2 2009. After Chile, Brazil is the second Latin American country where the Company is going to export its products.
The Company has now applied for admission of the GDRs issued against stock dividend to be admitted to trading on the London Stock Exchange's AIM market and admission is expected to occur on 4th August 2009. Following admission, the total number of GDRs in issue will be 40,911,186, each representing one ordinary share of Taka 10 and all having voting rights.
Financial
Net Sales increased by 39.5% to Tk. 2,314.71 million (2008: Tk. 1,659.34 million)
Profit before tax increased by 89.7% to Tk. 381.51 million (2008: Tk. 201.10 million)
EPS increased by 56% to Tk. 2.06 (2008: Tk. 1.32)
Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, commented:
"Over the last two years BPL faced serious challenges to sustain the Company's position at home and abroad. Despite these challenges, management have built a strong platform for the Company to grow significantly over the next few years. We have recently received GMP Certificates/Clearance from TGA Australia, Gulf Cooperation Council (GCC) and ANVISA, Brazil for our new oral solid dosage facility and inhaler facility. These approvals are major breakthroughs for the Company and bring us a step closer towards becoming a global pharmaceutical company over the next few years. "
The half yearly accounts can be viewed at the Company's website: www.beximcopharma.com
For further enquiries please contact:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 861 9151, ext.2080
Libertas Capital Corporate Finance
Jakob Kinde / Anthony Rowland
Tel: +44 (0)20 7569 9650
Financial Dynamics
Jonathan Birt / Susan Quigley
Tel: +44 (0)20 7269 7169
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.
The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.
Aktueller Kurs von Beximco 165,30 Taka = 1,69 Euro
Am Freitag in London 60.933 Stück Umsatz, letzter Kurs 0,49 Euro, also immer noch ca. 71 % Abgeld.
Am Freitag in London 60.933 Stück Umsatz, letzter Kurs 0,49 Euro, also immer noch ca. 71 % Abgeld.
Trading Spotlight
Aktueller Kurs von Beximco 176,00 Taka = 1,81 Euro
Am Freitag in London 334.355 Stück Umsatz, letzter Kurs 0,44 Euro, also immer noch über 75 % Abgeld.
Am Freitag in London 334.355 Stück Umsatz, letzter Kurs 0,44 Euro, also immer noch über 75 % Abgeld.
Antwort auf Beitrag Nr.: 37.524.239 von putzig am 06.07.09 15:13:26@putzig: Berechtigung für Stockdividende (übrigens nicht steuerpflichtig - Verfahren läuft aber noch)
Wer am 20.05.2009 Beximco Pharma GDR gekauft hat, wer definitiv stockdividendenberechtigt (siehe Mitteilung des Emitentten):
(1) The Record Date shall be on 25th May, 2009. The Shareholders whose names will appear in the Share Register of the
Company or in the Depository Register on that date will be entitled to attend the Annual General Meeting and to receive the
dividend.
http://www.londonstockexchange.com/exchange/prices-and-news/…
Die Bank ist für die ordnungsgemäße Einbuchung -Eintragung ins Aktienregister indirekt über ihre Lagerstelle zuständig.
Kann also nur empfehlen (wenn kein Nachweis zur Einbuchung vorhanden ist - ist bei mir zumindest noch Standard bei Flatex), schriftlich anfragen: Wann wurde Buchung vorgenommen? Danach in Einspruch gehen und ggf. Feststellungsklage (kann man selber formulieren) beim zuständigen Amtsgericht der Depotbank einreichen.
Ich hoffe aber, es war nur ein Buchungsfehler. Aber wenn man nicht aufpasst, kann bei der Bankenstruktur und der praktisch nicht vorhandenen Aufsicht und einer parteilichen Schlichtung alles passieren.
Gruß
UWWU
Wer am 20.05.2009 Beximco Pharma GDR gekauft hat, wer definitiv stockdividendenberechtigt (siehe Mitteilung des Emitentten):
(1) The Record Date shall be on 25th May, 2009. The Shareholders whose names will appear in the Share Register of the
Company or in the Depository Register on that date will be entitled to attend the Annual General Meeting and to receive the
dividend.
http://www.londonstockexchange.com/exchange/prices-and-news/…
Die Bank ist für die ordnungsgemäße Einbuchung -Eintragung ins Aktienregister indirekt über ihre Lagerstelle zuständig.
Kann also nur empfehlen (wenn kein Nachweis zur Einbuchung vorhanden ist - ist bei mir zumindest noch Standard bei Flatex), schriftlich anfragen: Wann wurde Buchung vorgenommen? Danach in Einspruch gehen und ggf. Feststellungsklage (kann man selber formulieren) beim zuständigen Amtsgericht der Depotbank einreichen.
Ich hoffe aber, es war nur ein Buchungsfehler. Aber wenn man nicht aufpasst, kann bei der Bankenstruktur und der praktisch nicht vorhandenen Aufsicht und einer parteilichen Schlichtung alles passieren.
Gruß
UWWU
Aktueller Kurs von Beximco 183,30 Taka = 1,91 Euro
Aktueller Kurs von Beximco unverändert 183,30 Taka = 1,91 Euro
Antwort auf Beitrag Nr.: 37.223.651 von uwwu am 20.05.09 22:54:25@uwwu: Problem record day für die Stockdividende.
Ich habe meine Beximco am 20.05.2009 in London gekauft. Stockdividende habe ich nicht erhalten.
Nach mdl. Aussage der dwp-Bank war der maßgebliche Stichtag der 19.05.2009. Hallo ??.
Kann es sein, dass die record day´s abweichen? Bei BoNY nach deinen Angaben ist es der 22.05.09. Bei Finanznachrichten habe ich auch schon was vom 25.05.09 gelesen. Oder könnte es so sein, dass der 19.05 nur eine interne Frist bei der dwp-Bank ist, für die rechtzeitige Weiterleitung an die evtl. eigentliche Depotbank in London ?
- Kennt sich hier jemand mit der Handhabung / Fristen / Lagerstelle in London aus ? Bitte um Informationen. Bin gerade ziemlich gefrustet.
Ich habe meine Beximco am 20.05.2009 in London gekauft. Stockdividende habe ich nicht erhalten.
Nach mdl. Aussage der dwp-Bank war der maßgebliche Stichtag der 19.05.2009. Hallo ??.Kann es sein, dass die record day´s abweichen? Bei BoNY nach deinen Angaben ist es der 22.05.09. Bei Finanznachrichten habe ich auch schon was vom 25.05.09 gelesen. Oder könnte es so sein, dass der 19.05 nur eine interne Frist bei der dwp-Bank ist, für die rechtzeitige Weiterleitung an die evtl. eigentliche Depotbank in London ?
- Kennt sich hier jemand mit der Handhabung / Fristen / Lagerstelle in London aus ? Bitte um Informationen. Bin gerade ziemlich gefrustet.
Durchsuchen
